AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22177374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous MID administration
Number of subjects: 73
Study 22177374 — intervention group
Group type: COMPARATOR
Intervention: Oral MID administration
Number of subjects: 73
Study 22177374 — intervention group
Group type: COMPARATOR
Intervention: Overall CYP3A activity
Number of subjects: 73
Study 19226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cell salvage
Number of subjects: 154
Study 19226044 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 154
Study 19226044 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood alone
Number of subjects: 154
Study 16879741 — intervention group
Group type: EXPERIMENTAL
Intervention: Salisbury Priority Scoring System (SPSS) used by patients
Number of subjects: 0
Study 16879741 — intervention group
Group type: COMPARATOR
Intervention: Salisbury Priority Scoring System (SPSS) used by surgeons
Number of subjects: 0
Study 12622624 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband UV-B (TL-01) phototherapy 3 times weekly
Number of subjects: 54
Study 12622624 — intervention group
Group type: COMPARATOR
Intervention: Oral 8-methoxypsoralen photochemotherapy (8-MOP PUVA) twice weekly
Number of subjects: 54
Study 10954911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon (5 x 10(6) U thrice weekly) plus vinblastine (6 mg/m2 every 14 days)
Number of subjects: 100
Study 10954911 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon monotherapy (15 x 10(6) U thrice weekly)
Number of subjects: 100
Study 9247766 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Losartan 50 mg
Number of subjects: 2
Study 9247766 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Enalapril 10 mg
Number of subjects: 2
Study 9247766 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg and Enalapril 20 mg
Number of subjects: 2
Study 8325192 — intervention group
Group type: EXPERIMENTAL
Intervention: Transproctoscopic Doppler sonography with local sclerosing treatment (6 ml of 5% phenol almond oil)
Number of subjects: 60
Study 8325192 — intervention group
Group type: COMPARATOR
Intervention: Injection of the same solution without Doppler investigation
Number of subjects: 60
Study 3568582 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockade (2 X 80 mg oral propranolol per day)
Number of subjects: 16
Study 3568582 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 16
Study 29979799 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Cryotherapy (CC)
Number of subjects: 40
Study 29979799 — intervention group
Group type: COMPARATOR
Intervention: Ice (ICE)
Number of subjects: 40
Study 27632270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsplinted implants
Number of subjects: 18
Study 27632270 — intervention group
Group type: COMPARATOR
Intervention: Splinted implants
Number of subjects: 18
Study 27632270 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants
Number of subjects: 18
Study 24935020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) titration
Number of subjects: 728
Study 24935020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 728
Study 22677046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual SLIT with TG and DM
Number of subjects: 30
Study 22677046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20435964 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention service
Number of subjects: 144
Study 20435964 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study 18618738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg on day 0, then 250 mg on day 14, day 28, and monthly thereafter)
Number of subjects: 20
Study 15984601 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Clickhaler
Number of subjects: 27
Study 15984601 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 27
Study 15984601 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (both devices)
Number of subjects: 27
Study 12888225 — intervention group
Group type: EXPERIMENTAL
Intervention: CC‐SIT
Number of subjects: 0
Study 12888225 — intervention group
Group type: COMPARATOR
Intervention: UPSIT
Number of subjects: 0
Study 12888225 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS‐III Logical Memory I
Number of subjects: 0
Study 10420346 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 10
Study 10420346 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 10
Study 10420346 — intervention group
Group type: COMPARATOR
Intervention: Medline interrogation
Number of subjects: 10
Study 10420346 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly identified trials
Number of subjects: 10
Study 7550956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic orthopaedic brace after 10-day plaster immobilization
Number of subjects: 20
Study 7550956 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing short-leg plaster cast for 25 days
Number of subjects: 20
Study 2046054 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention training
Number of subjects: 30
Study 2046054 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A management
Number of subjects: 30
Study 2046054 — intervention group
Group type: COMPARATOR
Intervention: Delayed Type A management intervention
Number of subjects: 30
Study 7453623 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine A/USSR/90/77
Number of subjects: 51
Study 7453623 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine A/Brazil/11/78
Number of subjects: 51
Study 31171039 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 436
Study 31171039 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 436
Study 28627914 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE group motivational interviewing intervention (4 sessions)
Number of subjects: 100
Study 26535968 — intervention group
Group type: COMPARATOR
Intervention: 10, 20, 30, or 40 mg hydrocodone-ER (single dose)
Number of subjects: 152
Study 26535968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 20, 30, or 40 mg hydrocodone-ER (twice-daily for 7 days)
Number of subjects: 152
Study 26535968 — intervention group
Group type: COMPARATOR
Intervention: 10 mg hydrocodone/325 mg acetaminophen IR
Number of subjects: 152
Study 26535968 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocodone-ER (single and multiple doses)
Number of subjects: 152
Study 26535968 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocodone-ER
Number of subjects: 152
Study 21594682 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and personalized congestion-guided ambulatory program (Group A) with close follow-up visits at 10 days, 20 days, and months 1, 2, 3 after discharge.
Number of subjects: 43
Study 21594682 — intervention group
Group type: COMPARATOR
Intervention: Conventional ambulatory follow-up (Group B) only at months 1, 2, 3 after discharge.
Number of subjects: 43
Study 21929716 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (Blink Intensive, Abbot Medical Optics Inc, CA, USA)
Number of subjects: 20
Study 21929716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypromellose (Artific, Farma-Lepori SA, Barcelona, Spain)
Number of subjects: 20
Study 20129552 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1294
Study 20129552 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1294
Study 17414929 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF (200/300 mg once daily) for 7 days followed by GS-9137/r (50/100 mg once daily) and GS-9137/r plus FTC/TDF in a crossover fashion for 10 days.
Number of subjects: 26
Study 17414929 — intervention group
Group type: COMPARATOR
Intervention: GS-9137/r (50/100 mg once daily) alone.
Number of subjects: 26
Study 15384797 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly mupirocin application (n = 18; men/women: 10/8; age: 55.3 ± 1.8 years)
Number of subjects: 36
Study 15384797 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly mupirocin application (n = 18; men/women: 11/7; age: 55.0 ± 2.3 years)
Number of subjects: 36
Study 14671238 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multidisciplinary stroke team (CST) approach
Number of subjects: 113
Study 14671238 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient rehabilitation and follow-up care
Number of subjects: 113
Study 14671238 — intervention group
Group type: EXPERIMENTAL
Intervention: Community group (CST)
Number of subjects: 113
Study 14671238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver satisfaction
Number of subjects: 113
Study 10511404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime i.v. (1 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Number of subjects: 186
Study 10511404 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime i.v. (2 g tid) + netilmicin i.v. (2 mg/kg bodyweight tid)
Number of subjects: 186
Study 7792725 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaccurate diagnostic tests (fibrinogen scanning)
Number of subjects: 0
Study 7792725 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 0
Study 7792725 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive screening tests supplemented by venography
Number of subjects: 0
Study 2037703 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 mg every night
Number of subjects: 112
Study 2037703 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa, 250 mg tid
Number of subjects: 112
Study 2037703 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine
Number of subjects: 112
Study 2037703 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 112
Study 2037703 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine and Methyldopa
Number of subjects: 112
Study 6454485 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (Provera)
Number of subjects: 70
Study 6454485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 70
Study 6454485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafoxidine
Number of subjects: 70
Study 31943216 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized periodontitis (GP) group
Number of subjects: 20
Study 31943216 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 20
Study 31287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for M2 occlusions
Number of subjects: 1003
Study 31287757 — intervention group
Group type: COMPARATOR
Intervention: Endovascular Treatment (EVT) for M1 occlusions
Number of subjects: 1003
Study 31287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for dominant M2 occlusions
Number of subjects: 1003
Study 31287757 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT) for nondominant M2 occlusions
Number of subjects: 1003
Study 29567116 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI 144/38.4, GFF MDI 18/9.6, GP MDI 144 μg
Number of subjects: 307
Study 29567116 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI 36/9.6, GP MDI 36, FF MDI 9.6 μg
Number of subjects: 307
Study 29567116 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 144/38.4 μg
Number of subjects: 307
Study 26864369 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg intake (1 additional egg (55 g)/d)
Number of subjects: 1032
Study 26864369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol intake (100 mg/d higher)
Number of subjects: 1032
Study 26864369 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg or cholesterol intakes
Number of subjects: 1032
Study 25146716 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial dual-ring wound protector (the Alexis Wound Protector)
Number of subjects: 0
Study 25146716 — intervention group
Group type: COMPARATOR
Intervention: No wound protector (current standard of care)
Number of subjects: 0
Study 22730491 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative Parenting Model (APM)
Number of subjects: 247
Study 22730491 — intervention group
Group type: COMPARATOR
Intervention: Control Group 1 (conventional dental education and behavior modification)
Number of subjects: 247
Study 22730491 — intervention group
Group type: COMPARATOR
Intervention: Control Group 2 (conventional behavior modification)
Number of subjects: 247
Study 22730491 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 247
Study 19186107 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music (MusiCure)
Number of subjects: 240
Study 19186107 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study 17937567 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (q.d.) or 60 mg twice daily (b.i.d.)
Number of subjects: 538
Study 17937567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 15834296 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 183
Study 15834296 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 183
Study 11870100 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic salpingectomy for hydrosalpinges prior to IVF
Number of subjects: 3
Study 11870100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 3
Study 9425914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin and albumin for 3 days
Number of subjects: 16
Study 9425914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin and albumin for 15 days
Number of subjects: 16
Study 7624264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice/day
Number of subjects: 271
Study 7624264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime
Number of subjects: 271
Study 7624264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 271
Study 7624264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 31053945 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280014
Number of subjects: 702
Study 31053945 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab-EU
Number of subjects: 702
Study 29444712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 210
Study 29444712 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 210
Study 29444712 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 26655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable collagen membrane (CM group)
Number of subjects: 24
Study 26655097 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable high-density polytetrafluoroethylene membrane (PTFE group)
Number of subjects: 24
Study 26655097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 24849545 — intervention group
Group type: EXPERIMENTAL
Intervention: IMC‐A12 + mitotane
Number of subjects: 20
Study 24849545 — intervention group
Group type: COMPARATOR
Intervention: Mitotane as a single agent
Number of subjects: 20
Study 22333737 — intervention group
Group type: EXPERIMENTAL
Intervention: VEG (vegetarian group avoiding meat, fish, and poultry)
Number of subjects: 39
Study 22333737 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH (group consuming fish 3-4 times weekly but avoiding meat and poultry)
Number of subjects: 39
Study 22333737 — intervention group
Group type: COMPARATOR
Intervention: OMN (control group consuming meat, fish, and poultry daily)
Number of subjects: 39
Study 19268878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders sent to both physician and patient
Number of subjects: 223
Study 19268878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders sent to patient only
Number of subjects: 223
Study 19268878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders sent to physician only
Number of subjects: 223
Study 19268878 — intervention group
Group type: COMPARATOR
Intervention: No reminders sent (control group)
Number of subjects: 223
Study 17299076 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroid ablation (TTA)
Number of subjects: 60
Study 17299076 — intervention group
Group type: COMPARATOR
Intervention: Near-total thyroidectomy (TX)
Number of subjects: 60
Study 15231507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on absolute risk reduction model
Number of subjects: 0
Study 15231507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on relative risk reduction model
Number of subjects: 0
Study 11688936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements (120 mL sip feed, 3 times daily, 540 kcal, 22.5 g protein per day)
Number of subjects: 381
Study 11688936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements
Number of subjects: 381
Study 11688936 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 381
Study 9387052 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT pitch 1.0
Number of subjects: 75
Study 9387052 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT pitch 1.5
Number of subjects: 75
Study 9387052 — intervention group
Group type: COMPARATOR
Intervention: Helical CT pitch 2.0
Number of subjects: 75
Study 8192610 — intervention group
Group type: EXPERIMENTAL
Intervention: First week of abstinence
Number of subjects: 179
Study 8192610 — intervention group
Group type: EXPERIMENTAL
Intervention: Second week of abstinence
Number of subjects: 179
Study 8192610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth week of abstinence
Number of subjects: 179
Study 3580240 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch exercises performed approximately 1 hour before operation
Number of subjects: 0
Study 3580240 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium without pretreatment (Control)
Number of subjects: 0
Study 28770628 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace without a patellar hole
Number of subjects: 108
Study 28770628 — intervention group
Group type: COMPARATOR
Intervention: Knee brace with a patellar hole
Number of subjects: 108
Study 26447067 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized palliative care (PC)
Number of subjects: 0
Study 26447067 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 26241537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enema 4 g/day (group A)
Number of subjects: 120
Study 26241537 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 3 mg/60 ml every day (group B)
Number of subjects: 120
Study 26241537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mesalazine and BDP (group C)
Number of subjects: 120
Study 23950156 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost plus timolol fixed combination (TTFC)
Number of subjects: 59
Study 23950156 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost plus timolol fixed combination (LTFC)
Number of subjects: 59
Study 20582993 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/carbidopa/entacapone (LCE)
Number of subjects: 747
Study 20582993 — intervention group
Group type: COMPARATOR
Intervention: L-dopa/carbidopa (LC)
Number of subjects: 747
Study 17882232 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 0
Study 17882232 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 14618372 — intervention group
Group type: EXPERIMENTAL
Intervention: True mud compresses
Number of subjects: 45
Study 14618372 — intervention group
Group type: COMPARATOR
Intervention: Attenuated mud compresses
Number of subjects: 45
Study 12933409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 3
Study 12933409 — intervention group
Group type: COMPARATOR
Intervention: Intermittent opiate regimen (IOR)
Number of subjects: 3
Study 12933409 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 3
Study 10097930 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5-4 mg t.i.d.)
Number of subjects: 424
Study 10097930 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (1.75-10.5 mg daily)
Number of subjects: 424
Study 8762729 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 8762729 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute GH
Number of subjects: 15
Study 8762729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days GH
Number of subjects: 15
Study 8762729 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks GH
Number of subjects: 15
Study 8762729 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment periods
Number of subjects: 15
Study 8762729 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 15
Study 1867965 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (150 mg racemic drug administered intravenously)
Number of subjects: 0
Study 1867965 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily orally)
Number of subjects: 0
Study 1867965 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (both enantiomers)
Number of subjects: 0
Study 6813952 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose group (carbohydrate alone)
Number of subjects: 37
Study 6813952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid group (excess amino acids, less carbohydrates)
Number of subjects: 37
Study 6813952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid group (carbohydrates and fats)
Number of subjects: 37
Study 30719645 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (average number of non-statin medications: 11.6, SD 5.0)
Number of subjects: 372
Study 30719645 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (adjusted for symptom burden)
Number of subjects: 372